Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
9.75
-0.02 (-0.20%)
At close: Jul 19, 2024, 4:00 PM
9.60
-0.15 (-1.54%)
Pre-market: Jul 22, 2024, 8:05 AM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 296 employees as of December 31, 2023. The number of employees increased by 28 or 10.45% compared to the previous year.
Employees
296
Change (1Y)
28
Growth (1Y)
10.45%
Revenue / Employee
$359,439
Profits / Employee
-$734,534
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Dec 31, 2019 | 29 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Owens & Minor | 22,200 |
| Artivion | 1,500 |
| Maravai LifeSciences Holdings | 650 |
| Silk Road Medical | 474 |
| Autolus Therapeutics | 463 |
| Relay Therapeutics | 323 |
| Ironwood Pharmaceuticals | 267 |
| Collegium Pharmaceutical | 197 |
ARQT News
- 27 minutes ago - Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL - GlobeNewsWire
- 12 days ago - FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age - GlobeNewsWire
- 18 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference - GlobeNewsWire
- 2 months ago - Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology - GlobeNewsWire
- 2 months ago - Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - GlobeNewsWire
- 3 months ago - Arcutis Appoints David Topper as Chief Financial Officer - GlobeNewsWire